KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Tax Provisions: 2016-2024

Historic Tax Provisions for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $18.9 million.

  • Amneal Pharmaceuticals' Tax Provisions fell 737.07% to -$23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 52.62%. This contributed to the annual value of $18.9 million for FY2024, which is 122.35% up from last year.
  • As of FY2024, Amneal Pharmaceuticals' Tax Provisions stood at $18.9 million, which was up 122.35% from $8.5 million recorded in FY2023.
  • Amneal Pharmaceuticals' Tax Provisions' 5-year high stood at $18.9 million during FY2024, with a 5-year trough of -$104.4 million in FY2020.
  • In the last 3 years, Amneal Pharmaceuticals' Tax Provisions had a median value of $8.5 million in 2023 and averaged $11.4 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Tax Provisions crashed by 127.23% in 2020 and then spiked by 122.35% in 2024.
  • Amneal Pharmaceuticals' Tax Provisions (Yearly) stood at -$104.4 million in 2020, then surged by 110.73% to $11.2 million in 2021, then slumped by 40.18% to $6.7 million in 2022, then increased by 26.87% to $8.5 million in 2023, then skyrocketed by 122.35% to $18.9 million in 2024.